March 2019 digital v1

More documents

Recommendations

Info

straight talk “EVERYBODY HAS TO DEVELOP THE WAY THEY ARE. TAKING ADVICE IS LIKE COPYING SOMEONE” Less focus on basic science and limited support for discovery research are the two issues the scientific community as well as governments all over the world should be seriously worried about today. Big pharmaceutical companies ignoring the serious threat of microbial resistance to existing antibiotics and not thinking about developing new ones is another dangerous trend that the world is facing at present, says PROF ADA E YONATH. The Chemistry Nobel Laureate, who was in India in February to deliver the keynote address at the International Conference on Advanced Chemical and Structural Biology - 2019 in Chennai, spoke to Future Medicine at length in an exclusive interview with Editor C H UNNIKRISHNAN. Edited excerpts: One of the key objectives of your path-breaking work on ribosomes was to help the development of new antibiotics. But, has it really resulted in the introduction of any in the market, especially in a situation where the existing ones are becoming less effective due to bacterial resistance? There are quite a few in the development stage across the globe, targeting ribosomes. But, in general, it seems that many of the big companies do not think that antibiotics are a profitable business for them. It is very unfortunate, and I wish they would think beyond profit and would take up more such projects and introduce them in the market quicker, considering the urgent need to save human life as antimicrobial resistance is a crucial health issue now. Why can’t big pharmaceutical companies, who often talk eloquently about philanthropy and social responsibility, work on these novel pathways, including your discovery, to develop new products that help combat this serious issue? There were several companies that showed interest in developing new products targeting proteins. Nothing much has happened so far as hardly anyone really worked to take it up. I know that the investment that is required to develop new drugs is high and that’s why they found it not profitable. I do not know if there are other reasons as well. One should ask them (the industry). You have been very vocal about the imminent health crisis that can manifest if there are no new antibiotics developed against multi-drug resistant bugs quickly. Do you think governments and not-for-profit organisations should step in? I don’t think governments can get into the business of product development and production, though it can facilitate and support research. It is the industry that should take them up. But, as you rightly said, one thing is sure that the crisis of drug resistant bacteria is going to be big in the world if there are no new antibiotics that enter the market soon. After your path-breaking work on identifying the ribosome structure and crystallising them, are there more research or 36 / FUTURE MEDICINE / March 2019
Prof Ada E Yonath PHOTO: UMESH GOSWAMI March 2019 / FUTURE MEDICINE / 37
Page 1 and 2: ₹ 250.00 VOL 5 | ISSUE 11 PAGES 1
Page 3 and 4: editor’s note editor’s note Mar
Page 5 and 6: 50 ORTHOPAEDICS SKELETAL TUBERCULOS
Page 7 and 8: A medical science and news magazine
Page 9 and 10: India and Norway extend cooperation
Page 12 and 13: INDIA HONOURS ITS ASHOK LAXMANRAO K
Page 14 and 15: policy GUIDELINES FOR NANO DRUGS Th
Page 16: column the catalyst An OYO model fo
Page 19 and 20: WAR TO END A SCOURGE India is battl
Page 21 and 22: in anti-TB armamentarium Conference
Page 23 and 24: world where TB is a major healthcar
Page 25 and 26: BATTLE FOR BEDAQUILINE Bedaquiline
Page 27 and 28: TREATMENT SUCCESS RATE 83% 54% 30%
Page 30 and 31: technology NGS BREAKS NEW PATH IN T
Page 32 and 33: drug approvals Priority review for
Page 34 and 35: of parasitic flatworms or trematode
Page 38 and 39: slug progressive work on the same h
Page 40 and 41: education MBBS INTERNS MAY SOON GET
Page 42 and 43: case reports WHEN PARKINSON’S STR
Page 44 and 45: case reports RECREATING THE IMPOSSI
Page 46 and 47: case reports FIGHTING OFF SWINE FLU
Page 48: column the cellview Taking the lead
Page 51 and 52: Diagnosing extra-pulmonary TB Tuber
Page 53 and 54: TUBERCULOSIS OF HIP A 38-year-old g
Page 55 and 56: AUGUST 2018/ FUTURE MEDICINE / 85
Page 57 and 58: The study demonstrates a less invas
Page 60: hospital news Apollo Hospitals hono
Page 63 and 64: BENIGN TO MALIGNANT Sequential muta
Page 65 and 66: GENETIC SCREENING FOR COLON CANCER
Page 67 and 68: to encourage patients and providers
Page 69 and 70: dose of measles vaccine was below t
Page 71 and 72: Robotic catheter for lung biopsy ge
Page 74: pharma ADVANCED WOUND THERAPY India
Page 77 and 78: was almost six months ago to consul
Page 79 and 80: the patent’s genetic result and t
Page 81 and 82: Ultrasound All-in-one imaging. Comp
Page 83: dalethyne reduces inflammation and
Page 86 and 87:
a lack of consensus among experts r
Page 88:
is indicated. Risk-reducing mastect
Page 91 and 92:
complex scenarios, referral to a ge
Page 93 and 94:
the cell walls of bacteria.” The
Page 96:
calendar Upcoming conferences MARCH
Page 99 and 100:
Sep 30 th - Oct 2 nd , 2019 - Mumba
show all

March 2019 digital v1

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?